Clinical trials: Central Obesity
Abdominal Obesity, Metabolic Syndrome
The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health
The prevalence of overweight and lifestyle related diseases such as cardiovascular disease (CVD) and type 2 diabetes (T2D) is increasing world wide.
- Conditions
- Abdominal Obesity, Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Disease
- Trial name
- MERITS (NCT02931630)
- Testing
- Whey protein powder, Maltodextrin powder, High fiber bread
- Where
- Denmark
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Obesity, Childhood
Community Active and Healthy Families
To address childhood overweight disparities among Latino children in immigrant families a pilot trial of a community-based obesity treatment program, Community Active and Healthy Families (AHF), among 5-12 year old overweight and…
- Trial name
- CommunityAHF (NCT04414553)
- Testing
- Community Active and Healthy Families
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Colorado, Denver
Obesity, Abdominal
Electroacupuncture Combined With Umbilical Moxibustion on Abdominal Obesity of Yang Deficiency
Obesity is a chronic metabolic disease that seriously harms human health, while abdominal obesity is more closely related to diseases such as type 2 diabetes, cardiovascular disease, and tumors, and has a higher risk.
- Trial name
- NCT04835181
- Testing
- Electroacupuncture combined with umbilical moxibustion, Electroacupuncture
- Volunteers
- 68 people
- Sponsor
- Hubei Hospital of Traditional Chinese Medicine
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Abdominal Obesity Metabolic Syndrome
Galantamine Effects in Patients With Metabolic Syndrome
It is recognized that inflammation can be modulated by cholinergic stimulation and that galantamine, an inhibitor of acetylcholinesterase enzyme with central nervous system action, has showed an anti-inflammatory effect, reducing…
- Trial name
- GALANTA-MS (NCT02283242)
- Testing
- Galantamine
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Angelman Syndrome, Smith-Magenis Syndrome
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population.
- Conditions
- Angelman Syndrome, Smith-Magenis Syndrome, X Fragile Syndrome, Epilepsy
- Trial name
- HOGRID (NCT04768803)
- Testing
- acylated and unacylated ghrelin dosages
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Obesity
Multi-Center Feasibility Study of Trans-oral Endoscopic Restrictive Implant System (TERIS) for Treatment of Obesity
The Barosense Trans-oral Endoscopic Restrictive Implant System (TERIS) is an investigational system being evaluated for safety The system uses endoscopic guidance to trans-orally implant a restrictive reservoir for food entering…
- Trial name
- NCT00707720
- Testing
- TERIS procedure
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- BaroSense Inc.